Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Diazoxide choline extended-release tablets demonstrated favorable safety profile across 4 years among patients with Prader-Willi Syndrome.

Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Early abdominal CT may be warranted among patients with unknown or uncertain biochemical screening results for primary aldosteronism.